Min Ren

Prof. Min Ren

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
JLJiahui Liang
Jiahui Liang
XWXin Wang
Xin Wang
JYJing Yang
Jing Yang
PSPeng Sun
Peng Sun
JSJingjing Sun
Jingjing Sun
MRMin Ren
Min Ren
Introduction: Breast cancer (BC) is now the most common type of cancer in women. Disulfidptosis is a new regulation of cell death (RCD). RCD dysregulation is causally linked to cancer. However, the comprehensive relationship between disulfidptosis and BC remains unknown. This study aimed to explore the predictive value of disulfidptosis-related genes (DRGs) in BC and their relationship with the TME.Methods: This study obtained 11 disulfidptosis genes (DGs) from previous research by Gan et al. RNA sequencing data of BC were downloaded from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus database (GEO) databases. First, we examined the effect of DG gene mutations and copy number changes on the overall survival of breast cancer samples. We then used the expression profile data of 11 DGs and survival data for consensus clustering, and BC patients were divided into two clusters. Survival analysis, gene set variation analysis (GSVA) and ss GSEA were used to compare the differences between them. Subsequently, DRGs were identified between the clusters used to perform Cox regression and least absolute shrinkage and selection operator regression (LASSO) analyses to construct a prognosis model. Finally, the immune cell infiltration pattern, immunotherapy response, and drug sensitivity of the two subtypes were analyzed. CCK-8 and a colony assay obtained by knocking down genes and gene sequencing were used to validate the model.Result: Two DG clusters were identified based on the expression of 11DGs. Then, 225 DRGs were identified between them. RS, composed of six genes, showed a significant relationship with survival, immune cell infiltration, clinical characteristics, immune checkpoints, immunotherapy response, and drug sensitivity. Low-RS shows a better prognosis and higher immunotherapy response than high-RS. A nomogram with perfect stability constructed using signature and clinical characteristics can predict the survival of each patient. CCK-8 and colony assay obtained by knocking down genes have demonstrated that the knockdown of high-risk genes in the RS model significantly inhibited cell proliferation.Discussion: This study elucidates the potential relationship between disulfidptosis-related genes and breast cancer and provides new guidance for treating breast cancer.

1 February 2022 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
YXYunfeng Xu
Yunfeng Xu
ZRZhiyao Ren
Zhiyao Ren
XWXin Wang
Xin Wang
MRMin Ren
Min Ren

25 September 2023 in Microsurgery
Verified
Journal Article
Closed access
JSJingjing Sun
Jingjing Sun
XWXiaodong Wu
Xiaodong Wu
JYJing Yang
Jing Yang
JLJiahui Liang
Jiahui Liang
MRMin Ren
Min Ren

10 October 2025 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
RXRuyue Xu
Ruyue Xu
JLJiahui Liang
Jiahui Liang
SZShuyuan Zhang
Shuyuan Zhang
PMPuseletso Moru
Puseletso Moru
KLKainan Liao
Kainan Liao
HZHaisheng Zhou
Haisheng Zhou

Verified
Journal Article
Open access
PDF file
JDJian Deng
Jian Deng
STShanshan Tong
Shanshan Tong
SLSiqi Liu
Siqi Liu
HZHaisheng Zhou
Haisheng Zhou
MRMin Ren
Min Ren
To critically synthesize evidence on treatment response in gynecomastia using a framework that distinguishes biological response, structural response, and patient-important benefit. We searched PubMed, PubMed Central, and targeted journals through 11 September 2026. Priority was given to gynecomastia-specific human studies; evidence from other breast systems, animal models, and general biomarker methodology was treated as indirect. The randomized anastrozole trial showed an endocrine effect but did not demonstrate superiority over placebo on the prespecified structural endpoint. Receptor expression in surgical specimens provides biological plausibility but does not establish receptor functionality, endocrine dependence, or predictive value. Stromal composition may influence lesion regression, but this remains a hypothesis requiring direct testing. Ultrasonography and elastography may support pretreatment characterization, but current studies do not validate imaging features as surrogates for fibrosis or endocrine responsiveness. Gynecomastia-derived organoids offer a disease-relevant model for functional studies, although donor numbers are small and endocrine responsiveness, cellular representativeness, and reproducibility across patients require further evaluation remain uncertain. Biological response, structural response, and patient-important benefit need not occur together or in a fixed sequence. Further research should link tissue and model findings to pretreatment markers, compare treatment benefits, and establish clinical utility before marker-guided care.